Thermo Fisher Scientific (TMO) Cash from Investing Activities (2009 - 2026)

Thermo Fisher Scientific has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$9.0 billion for Q1 2026.

• Quarterly Cash from Investing Activities fell 1600.38% year-over-year to -$9.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.5 billion (down 187.71% YoY) and the FY2025 annual result came in at -$4.0 billion, up 30.71% from the prior year.
• Cash from Investing Activities slipped to -$9.0 billion in Q1 2026, from $891.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $891.0 million in Q4 2025 and troughed at -$9.0 billion in Q1 2026.
• A 5-year average of -$1.5 billion and a median of -$527.0 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2025 — Cash from Investing Activities surged 4355.0% — and 2026, when it sank 1600.38%.
• Tracing TMO's Cash from Investing Activities over 5 years: stood at -$525.0 million in 2022, then increased by 28.38% to -$376.0 million in 2023, then jumped by 105.32% to $20.0 million in 2024, then jumped by 4355.0% to $891.0 million in 2025, then slumped by 1105.72% to -$9.0 billion in 2026.
• Business Quant data shows TMO's Cash from Investing Activities at -$9.0 billion in Q1 2026, $891.0 million in Q4 2025, and -$4.1 billion in Q3 2025.